Takeda and Trianni sign deal for transgenic mouse platform

Takeda has entered into a new license agreement that will give it access to the Trianni Mouse, an innovative and promising monoclonal antibody discovery platform.

Designed by life science company Trianni to exploit recent advances in DNA synthesis and genomic modification technology, the platform is distinguished by a novel chimeric gene segment design.

It will provide Takeda with easy access to a complete human antibody repertoire that has been optimised for the isolation of fully human therapeutics, expressed from chemically synthesised gene segments.

Dr Tetsuyuki Maruyama, general manager of the pharmaceutical research division of Takeda, said: "Takeda has a growing biologics pipeline and the Trianni Mouse is a natural addition to enhance our ongoing research capabilities in the area."

This comes after the Japanese pharmaceutical company announced positive data last month from a trial of lurasidone, a new therapy for the maintenance treatment of adults with schizophrenia that has been developed alongside Sunovion.